Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89180 | 0.83 | EGFR (0.33) | KDM4EMEN1KDM6BKDM4AALDH1A1 | |
| SCHEMBL21157146 | 0.64 | GPR3 (0.44) | KDM4EMEN1KDM6BKDM4AALDH1A1 | |
| SCHEMBL89122 | 0.62 | CA1 (0.41) | MEN1KMT2A | |
| SCHEMBL7858362 | 0.61 | — | — | |
| SCHEMBL21266565 | 0.60 | CA1 (0.41) | KDM4EMAPTKMT2ATDP1 | |
| SCHEMBL21032222 | 0.60 | PTGDR2 (0.34) | — | |
| SCHEMBL21157145 | 0.59 | GPR3 (0.44) | KDM4EMEN1KDM6BKDM4AALDH1A1 | |
| SCHEMBL9264880 | 0.59 | CHRNB2 (0.32) | — | |
| SCHEMBL88782 | 0.58 | CA9 (0.41) | MEN1KMT2A | |
| SCHEMBL844869 | 0.57 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8541585-B2 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090281161-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-11-12 | — | — | US | disclosed |
| US-20090270417-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | KDM4E 774/4885MEN1 3981/4885KDM6B 1145/4885 |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | KDM4E 792/4885MEN1 4045/4885KDM6B 1423/4885 |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | KDM4E 2064/4885MEN1 2753/4885KDM6B 2441/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | KDM4E 1562/4885MEN1 1437/4885KDM6B 1965/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | KDM4E 1290/4885MEN1 1534/4885KDM6B 2415/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | KDM4E 1597/4885MEN1 2386/4885KDM6B 2205/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | KDM4E 1650/4885MEN1 2336/4885KDM6B 2256/4885 |
| US-20090281161-A1 | Organic Compounds | REN, ACE, OTC | KDM4E 1567/4885MEN1 2965/4885KDM6B 2277/4885 |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | KDM4E 1117/4885MEN1 177/4885KDM6B 360/4885 |
| US-20090270417-A1 | Organic Compounds | REN, ACE, OTC | KDM4E 1567/4885MEN1 2965/4885KDM6B 2277/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | KDM4E 1140/4885MEN1 2812/4885KDM6B 1950/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | KDM4E 2265/4885MEN1 2792/4885KDM6B 3240/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | KDM4E 1011/4885MEN1 2834/4885KDM6B 1867/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | KDM4E 566/4885MEN1 3682/4885KDM6B 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.